The insider sales are routine post-earnings cashless option exercises by the CEO and a small CFO sale — the dollar amounts are trivial relative to market cap and carry no bearish signal. Monitor for any 10b5-1 plan disclosures or additional insider sales in the next 30 days, but this cluster alone does not warrant action. The more material event is the volixibat pipeline delay from the Aug 5 earnings release.
Price Chart
Executive Summary
Mirum Pharmaceuticals CEO Christopher Peetz and CFO Eric Bjerkholt sold a combined $1.75M in open-market stock within two days of the company's Q2 2026 earnings release, which showed strong 38% revenue growth but a significant GAAP EPS miss (-$1.06 vs -$0.75 consensus) and a key pipeline delay for volixibat. The CEO's sales ($1.98M total, including derivative exercises) and CFO's sale ($600K) represent ~0.03% of the $6.4B market cap, a trivial proportion that is likely liquidity-driven following option exercises rather than a bearish signal. The cluster is a net sell but the dollar amount is immaterial relative to company size, and the CEO's derivative exercise and same-day sale is a classic cashless exercise pattern, not an informed sell signal.
Key Financial Metrics
Key Facts
- CEO Peetz sold 20,000 shares via derivative exercise and open-market sales totaling ~$1.98M on Aug 10
- CFO Bjerkholt sold 6,001 shares for ~$600K on Aug 11
- Total cluster open-market sales: ~$2.55M (including CEO's derivative exercise cost of $58,720)
- Sales represent ~0.04% of MIRM's $6.4B market cap — well below the 0.1% materiality threshold
- Cluster occurred 5-6 days after Q2 earnings (Aug 5) which showed 38% revenue growth but a GAAP EPS miss and volixibat delay
- CEO's trades include a same-day derivative exercise and sale, consistent with a cashless stock option exercise pattern
Financial Impact
Total open-market sales of ~$2.55M represent ~0.04% of market cap — immaterial
Risk Factors
- Pipeline setback for volixibat (NDA delayed to H1 2027 after FDA recommended Phase 3 study)
- GAAP EPS miss (-$1.06 vs -$0.75 consensus) driven by heavy R&D/SG&A spending
- CEO and CFO both selling post-earnings could be perceived negatively by retail investors despite trivial size
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MIRM-1786608259408 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $102.24 $98.82 | ▼ −3.35% | ▼ −1.39% | $82.93 (−18.89%) |
Aug 12, 2026 7w ago | Insider Cluster | $98.97 $100.61 | ▲ +1.66% | ▲ +3.55% | $82.93 (−16.21%) |
Aug 11, 2026 7w ago | Insider Cluster | $98.97 $100.61 | ▼ −1.66% | ▼ −3.55% | $82.93 (+16.21%) |
Aug 10, 2026 7w ago | 144 | $98.23 $98.30 | ▲ +0.07% | ▲ +1.13% | $82.93 (−15.58%) |
Aug 5, 2026 8w ago | 8-K | $94.12 $100.63 | ▲ +6.92% | ▲ +6.32% | $82.93 (−11.88%) |
Jul 8, 2026 12w ago | Insider Cluster | $128.57 $105.79 | ▼ −17.72% | ▼ −20.99% | $82.93 (−35.50%) |
Jun 11, 2026 16w ago | Institutional Cluster | $99.54 $127.70 | ▲ +28.29% | ▲ +26.40% | $82.93 (−16.69%) |
Jun 10, 2026 16w ago | Insider Cluster | $94.00 $127.70 | ▲ +35.85% | ▲ +32.23% | $82.93 (−11.78%) |
Jun 2, 2026 17w ago | Insider Cluster | $91.84 $125.59 | ▲ +36.76% | ▲ +37.76% | $82.93 (−9.70%) |
Jun 1, 2026 17w ago | 144 | $92.17 $120.46 | ▲ +30.69% | ▲ +32.26% | $82.93 (−10.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access